SAN DIEGO–(BUSINESS WIRE)–#DMT–CB Therapeutics Inc., has successfully refined its in-house downstream processing, allowing for 99.6% pure CBC. a rare cannabinoid molecule found in trace quantities in cannabis and hemp. Using these patent-pending techniques, CB Therapeutics is able to drive down the cost of purification in parallel with increasing the purity to over 99%, considered a major breakthrough for any type of purification process.
“Using in-house equipment and personnel at our pilot facility in Carlsbad, we are able to start with our raw ingredients, make cannabinoids, and finally process them down to a pure extract,” said Dr. Jacob Vogan, CSO. “With the ability to refine cannabinoids like CBC, we can now port over these technologies for purification of other molecules in our portfolio, including other cannabinoids and tryptamines as well. These technologies are also applicable to the library of analogs we are building for various molecules,” Vogan said.
“The research and development process to produce biosynthetic molecules and developing a successful and efficient downstream process are the keys to manufacturing large quantities of pure products. Typically, most bioengineering and downstream technologies are able to produce small amounts of “dirty” samples, which in practice are not very useful. Having refined our downstream process, we are now looking to expand our manufacturing and purification capabilities to deliver pure cannabinoids, tryptamines, and their analogs to the market. The market is heating up for alternative and green technologies for the production of these molecules, and we are poised to take maximum advantage of our lead in the bioproduction and early IP filings for these molecules,” said Sher Ali Butt, CEO.
About CB Therapeutics
CB Therapeutics, Inc., located in San Diego, California, is a biotechnology company focusing on the innovative production of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms.